Rare Disease Strategy Consultants

Rare Disease Strategy Consultants

Strategy in rare disease requires specialist expertise and understanding. As a key part of CRA’s Life Sciences Practice, we understand the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.

We are rare disease specialists.

CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.

Rare disease areas
Rare disease engagements
since 2017

We provide a unique set of core offerings.


Our rare disease offerings span across the product lifecycle.

Early development
  • Early PMA assessment
  • Pipeline opportunity assessment
  • Diagnostics & screening
  • Incentives review
  • Licensing / commercially reasonable efforts disputes
Late development
  • Market access & evidence generation strateg
  • Payer value proposition
  • Patient finding
  • Landscape assessment & policy shaping
  • Launch pricing strategy
  • Payer negotiation
  • Launch excellence
  • Stakeholder engagement
  • Competitive simulations
  • Regulatory and P&R policies
  • Uptake and diffusion
Life cycle & LOE
  • Indication & geographic expansion
  • Competitor response strategies
  • Price/access/uptake benchmarking and assessments
  • LOE strategies

Featured consultants

Group Vice President and Life Sciences Practice Leader
Dr. Bell frequently testifies as an expert witness on damages in intellectual property, finance, and antitrust litigation in courts and arbitration proceedings in North America, Europe, Asia, and Australia. Dr. Bell’s business consulting engagements focus on the economics of business strategy, working with firms to develop sustainable competitive... Read more
Vice President
Cécile Matthews has more than 19 years of experience in strategy consulting for the life sciences industry. Her areas of expertise include pricing, reimbursement, and market access globally, and she is particularly renowned for her expert knowledge of France. Throughout her career as a consultant, Ms. Matthews has provided her clients with... Read more
Bhavesh Patel (PhD) is a Principal in the Life Sciences Practice at CRA. He has managed numerous strategy consulting projects on topics including pricing and market access, value perception, brand strategy, and launch readiness, engaging with pharmaceutical, biotech, and medical device companies. Bhavesh has experience across various therapeutic... Read more
Vice President
Ned Kitfield has extensive experience providing commercial decision support for large and small biotech, pharmaceutical, and healthcare companies.  While Ned has worked across a broad spectrum of therapeutic categories, he brings particular insight into rare and ultra-orphan diseases.  He expertise includes everything from commercialization... Read more
Vice President
Walter Colasante is a vice president in the Life Sciences Practice at CRA. He has experience in both the pharmaceutical and consulting industries. Walter has experience across a range of different therapeutic areas, most notably oncology, CNS, and rare diseases. Prior to his role at CRA, Walter was a senior principal at QuintilesIMS, now doing... Read more
Vice President
Mr. Brubacher has 25 years of pharmaceutical and biotech commercialization experience and has led cross-functional marketing and commercial teams during the development and launch of pharmaceutical products.  His expertise includes global commercial planning and market strategy, analytics, market simulation, rare diseases, lifecycle management,... Read more
Vice President
Tim Wilsdon focuses on projects involving the pharmaceuticals sector and the retail financial services market. As a vice president in CRA’s London office, Mr. Wilsdon is responsible for leading many pharmaceuticals projects in Europe. He commonly talks at European conferences on issues to do with pricing and reimbursement and the economics of... Read more